Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
MHLW Study Group Approves Interim Report toward Full-Scale Operation of MID-NET Database
The Ministry of Health, Labor and Welfare’s (MHLW) study group on medical information databases by and large approved an interim report on the Pharmaceuticals and Medical Devices Agency’s (PMDA) project to develop infrastructure for a large-scale medical information database (MID-NET)…
To read the full story
Related Article
- Final Report on MID-NET’s Full Operations Published
August 22, 2017
- Panel OKs 42.12 Million Yen Price Tag for Drug Makers’ MID-NET Use in PMS
July 20, 2017
- MHLW to Draw Up Guidelines on Use of MID-NET in Summer
April 28, 2017
- No Extra Fees Will Be Charged for Add’l Survey Items for MID-NET’s PMS Use: MHLW Working Group
March 23, 2017
- MID-NET Working Group Agrees on Flat Access Fees for Drug Makers’ PMS Use
November 30, 2016
- MID-NET Working Group Discusses Access Fee Calculations
October 28, 2016
- MID-NET Working Group Kicks Off Discussions on Access Fees
September 30, 2016
- MHLW Releases Interim Report for Full-Fledged Rollout of MID-NET
August 1, 2016
- Use of MID-NET in PMS Could Promote Comparisons of One’s Own Products with Other Treatments: FPMAJ Official
June 7, 2016
- MHLW Study Group Agrees MID-NET Database Should Be Made Available for Use in Post-Marketing Surveillance
May 13, 2016
REGULATORY
- CEA Review Has not Settled Debate, LDP Lawmaker Says
September 15, 2026
- Japan Pharma Investment Subgroup to Hold 1st Meeting September 18
September 14, 2026
- Japan Formally Joins Project Orbis for Cancer Drug Reviews
September 14, 2026
- MHLW Seeks 20.6 Billion Yen for MCM Stockpiles, Revenue Guarantees
September 14, 2026
- Japan Panel Backs Mandatory Medical Data Sharing by Major Hospitals
September 14, 2026
Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…